Of the patients with HER2-positive tumours , 45 ( 328 % , 250-407 ) of 137 patients achieved a pathological complete response with carboplatin compared with 50 ( 368 % , 287-449 ) of 136 without ( p = 0581 ; test for interaction p = 0015 ) .